Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 7/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365183 | 0.85 | MRGPRX1 (0.51) | MRGPRX1HSD17B10HPGDMKNK2ATM | |
| SCHEMBL3979886 | 0.83 | MRGPRX1 (0.49) | MRGPRX1HSD17B10HPGDMKNK2MAPT | |
| SCHEMBL4369869 | 0.77 | HSD17B10 (0.52) | HSD17B10HPGDMKNK2ATMMAPT | |
| SCHEMBL3977843 | 0.76 | HSD17B10 (0.48) | HSD17B10HPGDMKNK2ATMMAPT | |
| SCHEMBL2368112 | 0.75 | HPGD (0.57) | HSD17B10HPGDMKNK2ATMMAPT | |
| SCHEMBL13844360 | 0.74 | HSD17B10 (0.47) | MRGPRX1HSD17B10HPGDMKNK2ATM | |
| SCHEMBL15426163 | 0.74 | FGFR1 (0.67) | MKNK2MKNK1 | |
| SCHEMBL4902745 | 0.73 | KDR (0.57) | HSD17B10HPGDMKNK2MKNK1KDR | |
| SCHEMBL4902721 | 0.72 | SHMT2 (0.77) | HPGDMKNK2MAPTSMN1; SMN2MKNK1 | |
| SCHEMBL23630827 | 0.72 | HSD17B10 (1.00) | HSD17B10HPGDMAPTSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009058937-A2 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058937-A2 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | AHR, MALT1, ABL1 | MRGPRX1 2655/4885HSD17B10 1698/4885HPGD 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.